Statements (27)
| Predicate | Object |
|---|---|
| gptkbp:instanceOf |
gptkb:naphthoylindole
synthetic cannabinoid |
| gptkbp:actsOn |
CB1 receptor agonist
CB2 receptor agonist |
| gptkbp:binding_affinity_(CB1) |
0.46 nM
|
| gptkbp:binding_affinity_(CB2) |
0.69 nM
|
| gptkbp:CASNumber |
824959-81-1
|
| gptkbp:category |
gptkb:naphthoylindole
recreational drug cannabinoid receptor agonist |
| gptkbp:chemicalFormula |
C24H23NO
|
| gptkbp:discoveredBy |
gptkb:John_W._Huffman
|
| https://www.w3.org/2000/01/rdf-schema#label |
JWH-210
|
| gptkbp:IUPACName |
4-ethyl-1-naphthalenyl-(1-pentyl-1H-indol-3-yl)-methanone
|
| gptkbp:legal_status_(Germany) |
Anlage II controlled substance
|
| gptkbp:legal_status_(United_Kingdom) |
Class B drug
|
| gptkbp:legal_status_(United_States) |
Schedule I controlled substance
|
| gptkbp:molecularWeight |
341.45 g/mol
|
| gptkbp:namedAfter |
gptkb:John_W._Huffman
|
| gptkbp:relatedTo |
gptkb:JWH-018
gptkb:JWH-073 gptkb:JWH-122 |
| gptkbp:routeOfAdministration |
oral
inhalation |
| gptkbp:used_in |
scientific research
|
| gptkbp:bfsParent |
gptkb:JWH_cannabinoids
|
| gptkbp:bfsLayer |
6
|